Q3 EPS Estimate for Allurion Technologies Lifted by Analyst

Allurion Technologies Inc. (NYSE:ALUR) – Analysts at Roth Capital increased their Q3 2025 EPS estimates for shares of Allurion Technologies in a report issued on Wednesday, November 13th. Roth Capital analyst J. Wittes now anticipates that the company will post earnings of ($0.13) per share for the quarter, up from their previous estimate of ($0.14). Roth Capital has a “Strong-Buy” rating on the stock. The consensus estimate for Allurion Technologies’ current full-year earnings is ($0.40) per share. Roth Capital also issued estimates for Allurion Technologies’ Q4 2025 earnings at ($0.15) EPS, FY2025 earnings at ($0.54) EPS and FY2026 earnings at ($0.29) EPS.

ALUR has been the subject of several other reports. Roth Mkm assumed coverage on Allurion Technologies in a research report on Friday, September 6th. They set a “buy” rating and a $2.00 price target for the company. TD Cowen started coverage on Allurion Technologies in a report on Wednesday, October 2nd. They issued a “buy” rating and a $2.00 price objective for the company. Finally, Chardan Capital downgraded shares of Allurion Technologies from a “buy” rating to a “neutral” rating in a report on Thursday, November 14th. One investment analyst has rated the stock with a hold rating, three have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $2.88.

Allurion Technologies Price Performance

Shares of NYSE ALUR opened at $0.41 on Monday. The business has a 50-day moving average of $0.66 and a 200-day moving average of $1.01. The stock has a market capitalization of $26.37 million, a price-to-earnings ratio of -0.85 and a beta of -0.37. Allurion Technologies has a fifty-two week low of $0.31 and a fifty-two week high of $4.24.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in ALUR. CVI Holdings LLC bought a new stake in Allurion Technologies in the 2nd quarter valued at $520,000. Geode Capital Management LLC increased its holdings in shares of Allurion Technologies by 40.7% in the third quarter. Geode Capital Management LLC now owns 516,330 shares of the company’s stock valued at $317,000 after purchasing an additional 149,484 shares during the last quarter. Finally, Accredited Investors Inc. increased its holdings in shares of Allurion Technologies by 33.3% in the second quarter. Accredited Investors Inc. now owns 50,000 shares of the company’s stock valued at $50,000 after purchasing an additional 12,500 shares during the last quarter. 21.39% of the stock is currently owned by institutional investors.

About Allurion Technologies

Allurion Technologies Inc focuses on ending obesity with a weight loss platform to treat people who are overweight. Its platform, the Allurion Program, features swallowable and procedure-less intragastric balloon for weight loss (the Allurion Balloon), as well as offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion Virtual Care Suite.